Purine nucleoside analogues in the treatment of myleoid leukemias (Q35104351)

6 August 2017

1 reference

title

Purine nucleoside analogues in the treatment of myleoid leukemias (English)

1 reference

6 August 2017

1

Tadeusz Robak

1 reference

6 August 2017

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

44

1 reference

6 August 2017

3

1 reference

6 August 2017

391-409

1 reference

The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials

6 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Cladribine in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Fludarabine for treatment of adult acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Effects of 2-chloro-2'-deoxyadenosine 5'-triphosphate on DNA synthesis in vitro by purified bacterial and viral DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Cellular and clinical pharmacology of fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

The bioavailability of oral fludarabine phosphate is unaffected by food

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Vidarabine and 2-deoxycoformycin as antileukemic agents against monocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000035608

10.1080/1042819021000035608

21 January 2018

Identifiers

DOI

1 reference

release_zfyriijnmfaxxbon6glzozkj7i

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zfyriijnmfaxxbon6glzozkj7i

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

12688309

1 reference

PubMed ID

12688309